Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-07-31

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was conducted to demonstrate superiority of nateglinide in postprandial glucose fluctuation, dyslipidemia, and inflammatory status improvement.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes

NCT05629806

Type 2 Diabetes Blood Glucose Fluctuation

UNKNOWN PHASE3

Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients

NCT00461617

Diabetes

COMPLETED PHASE3

Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes

NCT01758471

Type 2 Diabetes

UNKNOWN PHASE4

A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes

NCT04591626

Type 2 Diabetes Mellitus

COMPLETED PHASE3

Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin

NCT02280486

Type 2 Diabetes

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nateglinide 120 mg

Nateglinide was taken orally 3 times daily, 10 minutes before meals for 4 weeks.

Group Type EXPERIMENTAL

Nateglinide 120 mg

Intervention Type DRUG

Nateglinide 120 mg was supplied as tablets.

Acarbose 50 mg

Acarbose 50 mg was taken orally 3 times daily, with the first bite of food at meals for 4 weeks.

Group Type ACTIVE_COMPARATOR

Acarbose 50 mg

Intervention Type DRUG

Acarbose 50 mg was supplied as tablets.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nateglinide 120 mg

Nateglinide 120 mg was supplied as tablets.

Intervention Type DRUG

Acarbose 50 mg

Acarbose 50 mg was supplied as tablets.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Starlix Glucobay

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly diagnosed type 2 diabetes mellitus patients
* HbA1c \> 6.5 and \< 9.0%
* Fasting fingertip capillary blood glucose (FCBG) \< 9 mmol/L after 2 weeks diet control

Exclusion Criteria

* History of acute metabolic complications in the past 3 months or of severe diabetic complications or severe infections or active substance abuse
* Liver disease
* Patients under oral hypoglycemic drugs and/or insulin treatment, or corticosteroid treatment within past 4 weeks

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No